Fungizone

Cerebral Cryptococcosis, Histoplasmosis, Coccidioidomycosis + 25 more
Treatment
28 FDA approvals
20 Active Studies for Fungizone

What is Fungizone

Amphotericin BThe Generic name of this drug
Treatment SummaryAmphotericin B is an antifungal medication used to treat a variety of fungal infections. It is effective against several species of fungi, such as Histoplasma capsulatum, Coccidioides immitis, and Candida species, among others. There are some species that are less susceptible to the drug, such as Pseudallescheria boydii and Fusarium sp., while Candida albicans is usually quite responsive. Amphotericin B has no effect on bacteria, rickettsiae, or viruses.
Fungizoneis the brand name
image of different drug pills on a surface
Fungizone Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Fungizone
Amphotericin B
1966
10

Approved as Treatment by the FDA

Amphotericin B, otherwise called Fungizone, is approved by the FDA for 28 uses like severe Fungal infection caused by Conidiobolus spp. and severe Fungal infection caused by Basidiobolus spp. .
severe Fungal infection caused by Conidiobolus spp.
severe Fungal infection caused by Basidiobolus spp.
severe Mucocutaneous leishmaniasis
severe Fungal infection caused by sporotrichosis spp.
severe North American blastomycosis
Histoplasmosis
Leishmaniasis, Visceral
Sporotrichosis
Mycoses
Cryptococcosis
Febrile Neutropenia
failed previous amphotericin B treatment
Used to treat failed previous amphotericin B treatment in combination with DL-dimyristoylphosphatidylcholine
severe Histoplasmosis
Visceral Leishmaniasis
severe Cryptococcosis
severe Systemic candidiasis
Mucocutaneous Leishmaniasis
Meningitis, Cryptococcal
Febrile Neutropenia
Leishmaniasis, Cutaneous
Gilchrist Disease
Coccidioidomycosis
Systemic candidiasis
Leishmaniasis, Mucocutaneous
Mycoses
Cerebral Cryptococcosis
HIV
Invasive Fungal Infections

Effectiveness

How Fungizone Affects PatientsAmphotericin B is an anti-fungal medicine that works in a laboratory setting against many different types of fungi, including Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus. It is usually effective against Candida albicans, but may be less effective against other species. It does not work against bacteria, rickettsiae, or viruses.
How Fungizone works in the bodyAmphotericin B is a medication that works by attaching to special molecules in the cell membrane of certain fungi. This creates a hole in the membrane, causing the cell to leak and die. Ergosterol, a molecule found in fungal cell membranes, is the primary target of Amphotericin B. By binding to ergosterol, Amphotericin B can stop the fungus from reproducing and ultimately kill it.

When to interrupt dosage

The suggested dosage of Fungizone is contingent upon the diagnosed condition, including Aspergillosis, grave Cryptococcosis and grave Mucocutaneous leishmaniasis. The sum of dosage fluctuates, in accordance with the approach of delivery outlined in the table beneath.
Condition
Dosage
Administration
Cerebral Cryptococcosis
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Cream - Topical, Lotion - Topical, Injection, Injection - Intravenous, Topical
Tuberculosis, Osteoarticular
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Cream - Topical, Lotion - Topical, Injection, Injection - Intravenous, Topical
Aspergillosis
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Cream - Topical, Lotion - Topical, Injection, Injection - Intravenous, Topical
Gilchrist Disease
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Cream - Topical, Lotion - Topical, Injection, Injection - Intravenous, Topical
Coccidioidomycosis
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Cream - Topical, Lotion - Topical, Injection, Injection - Intravenous, Topical
Systemic candidiasis
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Cream - Topical, Lotion - Topical, Injection, Injection - Intravenous, Topical
Mycoses
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Cream - Topical, Lotion - Topical, Injection, Injection - Intravenous, Topical
Aspergillosis
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Cream - Topical, Lotion - Topical, Injection, Injection - Intravenous, Topical
Cystitis
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Cream - Topical, Lotion - Topical, Injection, Injection - Intravenous, Topical
Histoplasmosis
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Cream - Topical, Lotion - Topical, Injection, Injection - Intravenous, Topical
Leishmaniasis, Cutaneous
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Cream - Topical, Lotion - Topical, Injection, Injection - Intravenous, Topical
Mycoses
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Cream - Topical, Lotion - Topical, Injection, Injection - Intravenous, Topical
Sporotrichosis
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Cream - Topical, Lotion - Topical, Injection, Injection - Intravenous, Topical
failed previous amphotericin B treatment
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Cream - Topical, Lotion - Topical, Injection, Injection - Intravenous, Topical
Leishmaniasis
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Cream - Topical, Lotion - Topical, Injection, Injection - Intravenous, Topical
Cryptococcosis
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Cream - Topical, Lotion - Topical, Injection, Injection - Intravenous, Topical
Histoplasmosis
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Cream - Topical, Lotion - Topical, Injection, Injection - Intravenous, Topical
Coccidioidomycosis
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Cream - Topical, Lotion - Topical, Injection, Injection - Intravenous, Topical
Cryptococcosis
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Cream - Topical, Lotion - Topical, Injection, Injection - Intravenous, Topical
Endophthalmitis
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Cream - Topical, Lotion - Topical, Injection, Injection - Intravenous, Topical

Warnings

There are 20 known major drug interactions with Fungizone.
Common Fungizone Drug Interactions
Drug Name
Risk Level
Description
Cyclosporine
Major
Amphotericin B may increase the nephrotoxic activities of Cyclosporine.
Neomycin
Major
The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Neomycin.
Tenofovir
Major
Amphotericin B may increase the nephrotoxic activities of Tenofovir.
Tenofovir alafenamide
Major
Amphotericin B may increase the nephrotoxic activities of Tenofovir alafenamide.
Tenofovir disoproxil
Major
Amphotericin B may increase the nephrotoxic activities of Tenofovir disoproxil.
Fungizone Toxicity & Overdose RiskThe lowest toxic dose of amphotericin B for rats has been found to be greater than 5gm/kg. Overdosing on amphotericin B can lead to cardiac and respiratory arrest.
image of a doctor in a lab doing drug, clinical research

Fungizone Novel Uses: Which Conditions Have a Clinical Trial Featuring Fungizone?

10 active trials are currently in progress to investigate the potential of Fungizone to address Meningitis, Fungal Histoplasmosis and Fungal Infections.
Condition
Clinical Trials
Trial Phases
Tuberculosis, Osteoarticular
0 Actively Recruiting
Coccidioidomycosis
0 Actively Recruiting
Cerebral Cryptococcosis
1 Actively Recruiting
Phase 2, Phase 3
Mycoses
0 Actively Recruiting
Aspergillosis
0 Actively Recruiting
Cryptococcosis
0 Actively Recruiting
Histoplasmosis
0 Actively Recruiting
Meningitis, Fungal
0 Actively Recruiting
Histoplasmosis
0 Actively Recruiting
Systemic candidiasis
4 Actively Recruiting
Phase 3, Phase 2
Febrile Neutropenia
3 Actively Recruiting
Phase 2, Not Applicable
Cryptococcosis
0 Actively Recruiting
talaromycosis
0 Actively Recruiting
Leishmaniasis, Cutaneous
0 Actively Recruiting
Invasive Fungal Infections
3 Actively Recruiting
Phase 3, Phase 2
Endophthalmitis
0 Actively Recruiting
Mycoses
0 Actively Recruiting
Leishmaniasis, Mucocutaneous
0 Actively Recruiting
Aspergillosis
0 Actively Recruiting
Gilchrist Disease
0 Actively Recruiting

Fungizone Reviews: What are patients saying about Fungizone?

5Patient Review
3/25/2008
Fungizone for Fungal Meningitis caused by Cryptococcus
I was treated with this medication for 10 days. I had some side effects, but they were manageable. The staff at University Hospital in Birmingham, AL were great and really helped me through the process.
3Patient Review
3/16/2010
Fungizone for Osteoporosis
This treatment really helped me. I'm grateful for modern medicine.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about fungizone

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is amphotericin same as fungizone?

"Amphotericin B is a drug used to prevent and treat deep, serious fungal infections. The usual formulation of amphotericin B is amphotericin B deoxycholate (Fungizone®)."

Answered by AI

How do you administer fungizone?

"Fungizone should be administered intravenously over a period of 2-6 hours, gradually increasing the initial daily dose of 0.25 mg/kg of body weight to 1.0 mg/kg, depending on individual response and tolerance."

Answered by AI

Is fungizone an antibiotic?

"Fungizone is an antifungal antibiotic that is used to treat serious fungal infections. It is usually given after other antifungal antibiotics have been unsuccessful."

Answered by AI

What is fungizone used for?

"Fungizone is a drug used to treat fungal infections. It may be used alone or with other medications. Fungizone belongs to a class of drugs called antifungals."

Answered by AI

Clinical Trials for Fungizone

Image of University of Alabama at Birmingham in Birmingham, United States.

Olfactory Training for HIV

18+
All Sexes
Birmingham, AL
The goal of this study is to examine two types of olfactory interventions (olfactory training vs overnight odor diffuser) in adults with HIV. The two research questions are: 1. Determine if participants find the intervention acceptable and assess feasibility of the study. 2. Determine if the intervention improves olfactory function and cognitive function. Participants will come to our office and be administered the baseline battery of questions including olfactory and cognitive performance tests. Then they will be randomized and sent home with one of the two interventions (below) in which they will engage in it for 8 weeks, after which they come back to our office for the posttest battery of questions including olfactory and cognitive performance test. 1. Olfactory Training at Home -- 4 scents in which they will smell twice a day for 8 weeks. 2. Overnight Diffuser Group -- a single scent diffuser that participants will turn on while they sleep and use for 8 weeks.
Phase < 1
Waitlist Available
University of Alabama at Birmingham
Image of Los Angeles General Medical Center in Los Angeles, United States.

Decision Support Tool for HIV Treatment

18+
All Sexes
Los Angeles, CA
This study is testing software designed to help healthcare providers choose the best HIV treatment combinations for their patients. HIV medicines, known as antiretroviral therapy (ART), can be complex to manage because the right regimen depends on many factors-such as drug resistance, other health conditions, and medication schedules. Many people with HIV are cared for by general clinicians who may not have access to HIV specialists, which can make treatment decisions more challenging. In this study, healthcare providers will use patient cases to compare standard HIV treatment resources with a new clinical decision support tool that gives evidence-based ART recommendations at the point of care. The investigators hypothesize that using the tool will help providers select treatment plans that better match clinical guidelines, make decisions faster, reduce mental effort, and increase overall satisfaction with the prescribing process.
Waitlist Available
Has No Placebo
Los Angeles General Medical CenterHayoun Lee, PhD
Image of University of North Carolina in Chapel Hill, United States.

MGD020 + MGD014 for HIV

18 - 65
All Sexes
Chapel Hill, NC
This research study aims to find out how safe and well tolerated the experimental study drugs are when given to persons with HIV (PWH) taking antiretroviral therapy (ART). The study treatments are MGD014 and MGD020, which are two antibodies developed specifically for HIV, and Vorinostat, an oral medication to help expose HIV in cells to the antibodies. The study will measure the impact of study treatment on non-active HIV in cells, and how long MGD014 and MGD020 stay in the body after they are given. In this study, participants will be randomly assigned to one of three groups. All participants receive MGD014 and MGD020, given sequentially as infusions through an IV for 4 doses. Participants in one group (group A) receive only MGD014 and MGD020. Participants in another group (group B) will stop taking their ART therapy for up to 8 weeks (a temporary treatment interruption (TTI)) while receiving MGD014 and MGD020. Participants in the third group (group C) receive Vorinostat in addition to MGD014 and MGD020. Total time of participation is about 8 months and involves 13 or 18 visits, depending on group assignment.
Phase 1
Recruiting
University of North CarolinaCynthia L. Gay, MD
Have you considered Fungizone clinical trials? We made a collection of clinical trials featuring Fungizone, we think they might fit your search criteria.Go to Trials
Have you considered Fungizone clinical trials? We made a collection of clinical trials featuring Fungizone, we think they might fit your search criteria.Go to Trials
Image of UCSF in San Francisco, United States.

N-803 for HIV

18 - 70
All Sexes
San Francisco, CA
Even though HIV medicine stops the virus from making more copies of itself, the virus remains in the body by hiding inside of immune cells. This hidden virus is referred to as the "latent reservoir." Researchers on this team are studying whether stimulating the immune system can change the nature of the latent reservoir and if this could help people control HIV without the need to take regular HIV medicine. This study is testing a drug called N-803. N-803 is also known as Interleukin-15 or "IL-15", a powerful and long lasting protein that can affect the immune system by stimulating immune cells such as CD8+ T cells and natural killer (NK) cells. CD8+ T cells and NK cells are both crucial for eliminating infected cells. The drug is FDA-approved for the treatment of bladder cancer, but in this study the drug is being used experimentally for HIV.
Phase 2
Waitlist Available
UCSF
Image of Alabama CRS (Site ID: 31788) in Birmingham, United States.

Dasatinib + Quercetin for HIV

18+
All Sexes
Birmingham, AL
This clinical trial is a Phase II study designed to test the safety and effectiveness of a combination of dasatinib and quercetin (D+Q) in improving physical function for people with HIV who are frail or prefrail. The study will involve 80 participants, all aged 50 or older, who have been living with HIV for at least 10 years determined to meet criteria for diagnosis of frail or prefrail and are currently on a stable antiretroviral therapy with viral suppression. Participants will be randomly assigned to one of two groups: one group will receive the D+Q treatment, and the other will receive a placebo. The treatment will be given in six cycles over 12 weeks, with participants taking the medication for two days followed by 12 days without treatment. After the 12-week treatment period, participants will be monitored for another 12 weeks to assess the long-term effects. The study aims to determine if D+Q can improve physical function and other health outcomes in this population. Randomization will be stratified by sex and age to ensure balanced groups.
Phase 2
Waitlist Available
Alabama CRS (Site ID: 31788) (+26 Sites)
Image of Yale University in New Haven, United States.

DynamiCare + Patient Navigation for Stimulant Use Disorder

18+
All Sexes
New Haven, CT
Justice-involved individuals face disproportionately high rates of stimulant use disorder and HIV, along with disrupted access to HIV treatment and prevention services like ART and PrEP. Contingency management (CM) is the most effective intervention for stimulant use, but its use in justice-involved populations has been limited by logistical and structural barriers. DynamiCare is an FDA-approved mobile app that delivers behavioral CM and has shown promise in reducing stimulant use, but its impact on HIV-related outcomes remains unknown. The RESTORE study (Recovery and Engagement for Stimulant Users on Re-entry) will evaluate whether combining DynamiCare with patient navigation (DynamiCare-plus) improves PrEP/ART initiation and reduces stimulant use among individuals recently released from justice settings. The R61 phase will assess feasibility, acceptability, and preliminary effectiveness among 40 participants. If milestones are met, the R33 phase will scale to a randomized controlled trial with 252 participants to assess effectiveness, implementation, and cost. This scalable, mobile approach has the potential to address a critical gap in care for a highly vulnerable population.
Waitlist Available
Has No Placebo
Yale University (+1 Sites)Ank Nijhawan, MD
Have you considered Fungizone clinical trials? We made a collection of clinical trials featuring Fungizone, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security